Reported Growth Masks Continuing Core Decline – Patience Required

What happened

Xerox's Q1 headline revenue jumped 27% and adjusted EBIT tripled, largely from the Lexmark acquisition. However, pro forma revenue fell 3.7%, operating cash flow was negative $144M, and pro forma margins barely budged. The high leverage (net debt $3.7B) and heavy near-term maturities ($845M in 2028) leave little room for error. The article's $6 price target relies on synergy delivery that has not yet materially shown up in normalized results. Investors should not be misled by the reported optics; the underlying business continues to shrink.

Implication

Xerox must show two to three quarters of pro forma revenue stabilization and genuine margin expansion (driven by synergies, not mix). Until then, the equity remains an option on deleveraging, not a value investment. The attractive entry is near $2.75 per the master report, with a re-assessment in 3-6 months after more clean data.

Thesis delta

The thesis shifts from bullish on reported turnaround to cautious on underlying deterioration. While the article highlights 'solid returns', the normalized numbers reveal a business still in decline with high leverage and weak cash generation. The path to value creation requires observable pro forma improvement, not just acquisition accounting optics.